Literatur
-
1
Adachi J D, Bensen W G, Brown J, Hanley D, Hodsman A, Josse R, Kendler D L, Lentle B, Olszynski W, Ste-Marie L G, Tenenhouse A, Chines A A.
Intermittent etidronate therapy to prevent
corticosteroid-induced osteoporosis.
N Engl J
Med.
1997;
337
382-387
-
2
Adachi J D, Roux C, Pitt P I, Cooper C, Moniz C, Dequeker J, Ioannidis G, Cawley M I, Jenkins E A, Walker-Bone K E, Pack S, Stephenson G F, Laan R F, Brown J, Geusens P.
A pooled data analysis on the use of intermittent cyclical
etidronate therapy for the prevention and treatment of corticosteroid induced
bone loss.
J
Rheumatol.
2000;
27
2424-2431
-
3
Adachi J D, Saag K G, Delmas P D, Liberman U A, Emkey R D, Seeman E, Lane N E, Kaufman J M, Poubelle P E, Hawkins F, Correa-Rotter R, Menkes C J, Rodriguez-Portales J A, Schnitzer T J, Block J A, Wing J, McIlwain H H, Westhovens R, Brown J, Melo-Gomes J A, Gruber B L, Yanover M J, Leite M O, Siminoski K G, Nevitt M C, Sharp J T, Malice M P, Dumortier T, Czachur M, Carofano W, Daifotis A.
Two-year effects of alendronate on bone mineral density and
vertebral fracture in patients receiving glucocorticoids: a randomized,
double-blind, placebo-controlled extension trial.
Arthritis
Rheum.
2001;
44
202-211
-
4
Bamberger C M, Schulte H M.
Molecular mechanisms of dissociative glucocorticoid
activity.
Eur J Clin
Invest.
2000;
30
6-9
(Suppl
3)
-
5
Canalis E, Delany A M.
Mechanisms of glucocorticoid action in bone.
Ann N
Y Acad
Sci.
2002;
966
73-81
-
6
Chapuy M C, Arlot M E, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas P D, Meunier P J.
Vitamin D3 and calcium to prevent hip fractures in the
elderly women.
N Engl J
Med.
1992;
327
1637-1642
-
7
Chapuy M C, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, Garnero P, Meunier P J.
Combined calcium and vitamin D3 supplementation in elderly
women: confirmation of reversal of secondary hyperparathyroidism and hip
fracture risk: the Decalyos II study.
Osteoporos
Int.
2002;
13
257-264
-
8
Crandall C.
Parathyroid hormone for treatment of
osteoporosis.
Arch Intern
Med.
2002;
162
2297-2309
-
9
Hofbauer L C, Gori F, Riggs B L, Lacey D L, Dunstan C R, Spelsberg T C, Khosla S.
Stimulation of osteoprotegerin ligand and inhibition of
osteoprotegerin production by glucocorticoids in human osteoblastic lineage
cells: potential paracrine mechanisms of glucocorticoid-induced
osteoporosis.
Endocrinology.
1999;
140
4382-4389
-
10
Hofbauer L C, Khosla S, Dunstan C R, Lacey D L, Boyle W J, Riggs B L.
The roles of osteoprotegerin and osteoprotegerin ligand in
the paracrine regulation of bone resorption.
J Bone Miner
Res.
2000;
15
2-12
-
11
Jilka R L, Weinstein R S, Bellido T, Roberson P, Parfitt A M, Manolagas S C.
Increased bone formation by prevention of osteoblast
apoptosis with parathyroid hormone.
J Clin
Invest.
1999;
104
439-446
-
12
Jones A, Fay J K, Burr M, Stone M, Hood K, Roberts G.
Inhaled corticosteroid effects on bone metabolism in asthma
and mild chronic obstructive pulmonary disease.
Cochrane Database
Syst
Rev.
2002;
CD003537
-
13
Lane N E, Sanchez S, Modin G W, Genant H K, Pierini E, Arnaud C D.
Parathyroid hormone treatment can reverse
corticosteroid-induced osteoporosis. Results of a randomized controlled
clinical trial.
J Clin
Invest.
1998;
102
1627-1633
-
14
Leischker H, Kolb G F.
Therapeutical use of parathyroid hormone.
Dtsch Med
Wochenschr.
2002;
127
624-626
-
15
Luckman S P, Hughes D E, Coxon F P, Graham R, Russell G, Rogers M J.
Nitrogen-containing bisphosphonates inhibit the mevalonate
pathway and prevent post-translational prenylation of GTP-binding proteins,
including Ras.
J Bone Miner
Res.
1998;
13
581-589
-
16
Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat J M, Setoain J.
Vertebral fractures in steroid dependent asthma and
involutional osteoporosis: a comparative
study.
Thorax.
1991;
46
803-806
-
17
Nutall M E, Patton A J, Olivera D L, Nadeau D P, Gowen M.
Human trabecular bone cells are able to express both
osteoblasic and adipocytic phenotype: implications for osteopenic
disorders.
J Bone Miner
Res.
1998;
13
371-382
-
18
Nuttall M E, Gimble J M.
Is there a therapeutic opportunity to either prevent or treat
osteopenic disorders by inhibiting marrow
adipogenesis?.
Bone.
2000;
27
177-184
-
19
Okada N, Nomura M, Morimoto S, Ogihara T, Yoshikawa K.
Bone mineral density of the lumbar spine in psoriatic
patients with long term etretinate therapy.
J
Dermatol.
1994;
21
308-311
-
20
Patschan D, Loddenkemper K, Buttgereit F.
Molecular mechanisms of glucocorticoid-induced
osteoporosis.
Bone.
2001;
29
498-505
-
21
Peacey S R, Guo C Y, Robinson A M, Price A, Giles M A, Eastell R, Weetman A P.
Glucocorticoid replacement therapy: are patients over treated
and does it matter?.
Clin Endocrinol
(Oxf).
1997;
46
255-261
-
22
Pearce G, Tabensky D A, Delmas P D, Baker H W, Seeman E.
Corticosteroid-induced bone loss in men.
J Clin
Endocrinol
Metab.
1998;
83
801-806
-
23
Pereira R C, Delany A M, Canalis E.
Effects of cortisol and bone morphogenetic protein-2 on
stromal cell differentiation: correlation with CCAAT-enhancer binding protein
expression.
Bone.
2002;
30
685-691
-
24
Plotkin L I, Weinstein R S, Parfitt A M, Roberson P K, Manolagas S C, Bellido T.
Prevention of osteocyte and osteoblast apoptosis by
bisphosphonates and calcitonin.
J Clin
Invest.
1999;
104
1363-1374
-
25
Reid D M, Hughes R A, Laan R F, Sacco-Gibson N A, Wenderoth D H, Adami S, Eusebio R A, Devogelaer J P.
Efficacy and safety of daily risedronate in the treatment of
corticosteroid-induced osteoporosis in men and women: a randomized trial.
European Corticosteroid-Induced Osteoporosis Treatment Study.
J Bone
Miner
Res.
2000;
15
1006-1013
-
26
Rossouw J E, Anderson G L, Prentice R L, LaCroix A Z, Kooperberg C, Stefanick M L, Jackson R D, Beresford S A, Howard B V, Johnson K C, Kotchen J M, Ockene J.
Risks and benefits of estrogen plus progestin in healthy
postmenopausal women: principal results From the Women’s Health
Initiative randomized controlled
trial.
Jama.
2002;
288
321-333
-
27
Rubin M R, Bilezikian J P.
Clinical review 151: The role of parathyroid hormone in the
pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the
evidence.
J Clin Endocrinol
Metab.
2002;
87
4033-4041
-
28
Saag K G, Emkey R, Schnitzer T J, Brown J P, Hawkins F, Goemaere S, Thamsborg G, Liberman U A, Delmas P D, Malice M P, Czachur M, Daifotis A G.
Alendronate for the prevention and treatment of
glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis
Intervention Study Group.
N Engl J
Med.
1998;
339
292-299
-
29
Tauchmanova L, Rossi R, Nuzzo V, del Puente A, Esposito-del Puente A, Pizzi C, Fonderico F, Lupoli G, Lombardi G.
Bone loss determined by quantitative ultrasonometry
correlates inversely with disease activity in patients with endogenous
glucocorticoid excess due to adrenal mass.
Eur J
Endocrinol.
2001;
145
241-247
-
30
Van Staa T P, Leufkens H G, Abenhaim L, Zhang B, Cooper C.
Use of oral corticosteroids and risk of
fractures.
J Bone Miner
Res.
2000;
15
993-1000
-
31
Vayssiere B M, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, Gronemeyer H, Resche-Rigon M.
Synthetic glucocorticoids that dissociate transactivation and
AP-1 transrepression exhibit antiinflammatory activity in vivo.
Mol
Endocrinol.
1997;
11
1245-1255
-
32
Viereck V, Emons G, Lauck V, Frosch K H, Blaschke S, Grundker C, Hofbauer L C.
Bisphosphonates pamidronate and zoledronic acid stimulate
osteoprotegerin production by primary human osteoblasts.
Biochem
Biophys Res
Commun.
2002;
291
680-686
-
33
Wallach S, Cohen S, Reid D M, Hughes R A, Hosking D J, Laan R F, Doherty S M, Maricic M, Rosen C, Brown J, Barton I, Chines A A.
Effects of risedronate treatment on bone density and
vertebral fracture in patients on corticosteroid therapy.
Calcif
Tissue
Int.
2000;
67
277-285
-
34
Weinstein R S, Chen J R, Powers C C, Stewart S A, Landes R D, Bellido T, Jilka R L, Parfitt A M, Manolagas S C.
Promotion of osteoclast survival and antagonism of
bisphosphonate-induced osteoclast apoptosis by glucocorticoids.
J
Clin
Invest.
2002;
109
1041-1048
-
35
Weinstein R S, Jilka R L, Parfitt A M, Manolagas S C.
Inhibition of osteoblastogenesis and promotion of apoptosis
of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their
deleterious effects on bone.
J Clin
Invest.
1998;
102
274-282
-
36
Weinstein R S, Manolagas S C.
Apoptosis and osteoporosis.
Am J
Med.
2000;
108
153-164
-
37
Zelissen P M, Croughs R J, van Rijk P P, Raymakers J A.
Effect of glucocorticoid replacement therapy on bone mineral
density in patients with Addison disease.
Ann Intern
Med.
1994;
120
207-210
Prof. Dr. M. Hüfner
Schwerpunkt Endokrinologie, Abteilung Gastroenterologie und
Endokrinologie, Zentrum Innere Medizin, Georg-August-Universität
Robert Koch-Straße 40
37075 Göttingen
Phone: 0551/398902
Fax: 0551/392063
Email: mhuefner@med.uni-goettingen.de
